The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study: Baseline clinical and functional characteristics and antipsychotic use patterns in Turkey

Klinik Psikofarmakoloji Bulteni

Volumn 14, Issue 3, 2004, Pages 132-142

  Şaylan, Mete ^a   Alptekin, Köksal ^b   Akdemir, Asena ^c   Tetik, Erkan ^d   Korb, Frans A ^e  

^a Eli Lilly Medical Department   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

^c SSK Etlik Hospital   (Turkey)

^d Eli Lilly Medical Department   (Turkey)

^e Eli Lilly Regional Operations   (Austria)

Author keywords

Antipsychotic agents; Clinical characteristics; Functional characteristics; IC SOHO; Outpatients; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; HYPNOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

AKATHISIA; ALCOHOLISM; AMENORRHEA; ARTICLE; DRUG USE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GYNECOMASTIA; HEALTH CARE UTILIZATION; HUMAN; IMPOTENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MENTAL HEALTH CARE; OBESITY; OBSERVATION; OUTCOMES RESEARCH; PARKINSONISM; PATIENT COMPLIANCE; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SUBSTANCE ABUSE; TARDIVE DYSKINESIA; TURKEY (REPUBLIC);

EID: 4744375248     PISSN: 10177833     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Day S. Dictionary for Clinical Trials. Chichester: Wiley, 1999
2. Horwitz RI, Viscoli CM, Clemens JD, Sadock RT. Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med 1990; 89: 630-638
3. Sacristan JA, Soto J, Galende I, Hylan TR. A review of methodologies for assessing drug effectiveness and a new proposal: randomised database studies. Clin Ther 1997; 19: 1510-1517
4. Jones TC. Call for a new approach to the process of clinical trials and drug registration. BMJ 2001; 322: 920-923
5. McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Interpreting the evidence: choosing between randomised and non-randomised studies. MBJ 1999; 319: 312-315
6. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Choosing between randomised and non-randomised studies: a systematic review. Health Technol Assess 1998; 2: 1-124
7. Concato J, Shah N, Horwitz RI. Randomised, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892
8. Benson K, Hartz AJ. A comparison of observational studies and randomised, controlled trials. N Engl J Med 2000; 342: 1878-1886
9. Byar DP, Simon RM, Friedewald WT, Schlesselman JJ, DeMets, DL, Ellenberg JH, Gail MH, Ware JH. Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med 1976; 295: 74-80
10. Pocock SJ. Randomized Trials or Observational Tribulations? N Engl J Med 2000; 342: 1907-1909
11. Kunz R, Khan KS, Neumayer HH. Observational studies and randomised trials. N Engl J Med 2000; 343: 1194-1197
12. Ioannidis JPA, Haidich AB, Lau J. Any casualties in the clash of randomised and observational evidence? BMJ 2001; 322: 879-880
13. Barton S. Which clinical studies provide the best evidence? BMJ 2000; 321: 255-256
14. Tsuang MT. Observational versus Experimental Studies: Would the Results Be Similar? Psychosom Med 1999; 61: 146-147
15. Brambilla P, Barale F, Caverzasi E, Tognoni G, Barbui C. Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies. Int Clin Psychopharmacol 2002; 17: 189-195
16. Wehnert A. The European Post-marketing Observational Serdolect [EPOS) Project: increasing our understanding of schizophrenia therapy. Int Clin Psychopharmacol 1998; 13(Suppl 3): S27-30
17. Fraile GM, Echevaria SR, Arrillaga GA, Junquera MG. Risperidone in the early treatment of first-episode psychosis: a two-year follow-up study. Acta Esp Psiquiatr 2002; 30: 142-152
18. Hamel B, Courtet P, Vergnes C, Boulenger JP. Clinical impact of atypical antipsychotics: prospective 6-month study of inpatients treated with risperidone or olanzapine. Therapie 2001; 56: 645-652
19. Sacristan JA, Gomez JC, Ferre F, Gascon J Perez Bravo A, Olivares JM. Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study. Actas Esp Psiquiatr 2001; 29: 25-32
20. Sacristan JA, Gomez JC, Montejo AL, Vieta E, Gregor KJ And The Efeso Study Group. Doses of Olanzapine, Risperidone, and Haloperidol Used in Clinical Practice: Results of a Prospective Pharmacoepidemiologic Study. Clin Ther 2000 May; 22: 583-599
21. Sacristan GJC, Hernandez, J Breier A, Carrasco RP, Saiz AC, Carbonell FE. The safety of olanzapine compared with other antpsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia J Clin Psychiatry 2000; 61: 335-343
22. Wilton LV, Heeley EL, Pickering RM, Shakir SA. Comparative study of mortality rates and cardiac dysrythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychpharmacol 2001; 15: 120-126
23. Williams A. EuroQol - a new facility for the measurement of health related quality of life. Health Policy 1990; 16: 199-208
24. Rush AJ, Pincus HA, First MB, et al. Handbook of Psychiatric Measures. Washington: American Psychiatric Association, 2000
25. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impression (CGI) scale for use in bipolar illness(BP): the CGI-BP. Psychiatry Res 1997; 73: 159-171
26. Kasper S, Rosillon D, Duchesne I Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 2001; 16: 179-187
27. Thornicroft G, Leese M, Tansella M, Howard L, Toulmin H, Herran A, Schene A. Gender differences in living with schizophrenia. A cross-sectional European multi-site study. Schizophr Res 2002; 57: 191-200
28. Gomez JC, Sacristan JA, Hernandez J, Breier A, Ruiz Carrasco P, Anton Saiz C, Fontova Carbonell E. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). J Clin Psychiatry 2000; 61: 335-343
29. Alvarez E, Bobes J, Gomez JC, Sacristan JA, Canas F, Carrasco JL, Gascon J, Gutierrez M; EUROPA Study Group. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. Eur Neuropsychopharmacol 2003; 13: 39-48
30. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, Awad A. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002; 57: 201-208
31. Hamilton SH, Edgell ET, Revicki DA & Breier A Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000; 15: 245-255
32. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, Wright P, Knapp M. on behalf of the SOHO study group. The European schizophrenia outpatient health outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003; 107: 222-232
33. Ritsner M, Ponizovsky A, Endicott J, Nechamkin Y, Rauchverger B, Silver H, Modai I. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol 2002; 12: 31-38
34. Parepally H, Chakravorty S, Levine J, Brar JS, Patel AM, Baird JW, Chalasani L, Delaney JA, Atzert R, Chengappa KN. The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents. A naturalistic study at a state psychiatric hospital. Prog NeuroPsychopharmacol Biol Psychiatry 2002; 26: 437-440
35. Rodriguez-Perez V, Lopez A, Blanco C, Pena C, Lopez A, Abel A, Gomez Y, Ferreiro MJ, Rego C, Lopez A, Cudeino F, Alvarez V, Prieto R, Ciudad A. Olanzapine for the treatment of chronic refractory schizophrenia: A 12-month follow-up naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1055-1062
36. Perkins DO. Predictors of non-compliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121-1128
37. The Expert Consensus Panels. The Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J Clin Psychiatry 1999; 60(Suppl. 11): 1-82
38. Kupfer DJ& Sartorius N. The usefulness and use of second-generation antipsychotic medications Curr Opin Psychiatry 2002; 15(Suppl. 1): 1-52
39. Compton, Miller AH. Antipsychotic-Induced Hyperprolactinemia and Sexual Dysfunction. Psychopharmacol Bull 2002; 36: 1-143
40. Chaves AC, Seeman MV, Mari JJ, Maluf A. Schizophrenia: impact of positive symptoms on gender social role. Schizophr Res. 1993; 11: 41-45
41. Alptekin K, Mete L, Yazici K, Kültür S, Cirit H, Saylan M. A multicenter 1-year follow-up study of schizophrenia: Co-morbid alcohol and tobacco abuse in schizophrenia. Poster at 37th Turkish National Congress of Psychiatry. P144-145
42. Knegtering H, Van Der Moolen AE, Castelein S, Kluiter H, Van Den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003; 28 (Suppl 2): 109-123
43. Shtasel DL, Gur RE, Gallacher F, Heimberg C, Gur RC. Gender differences in the clinical expression of schizophrenia. Schizophr Res 1992; 7: 225-231
44. Roder-Wanner UU, Priebe S. Objective and subjective quality of life of first-admitted women and men with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1998; 248: 250-258
45. Gur RE, Petty RG, Turetsky BI, Gur RC. Schizophrenia throughout life: sex differences in severity and profile of symptoms. Schizophr Res. 1996; 21: 1-12